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Abstract: There are indications that serotonergic neurotransmission is disturbed in several psychiatric disorders. One explanation 
may be disturbed transport of tryptophan (precursor for serotonin synthesis) across cell membranes. Human fibroblast cells offer an 
advantageous model to study the transport of amino acids across cell membranes, since they are easy to propagate and the environmental 
factors can be controlled. The aim of this study was to functionally characterize tryptophan transport and to identify the main transporters 
of tryptophan in fibroblast cell lines from healthy controls.
Tryptophan kinetic parameters (Vmax and Km) at low and high concentrations were measured in fibroblasts using the cluster tray 
method. Uptake of 3H (5)-L-tryptophan at different concentrations in the presence and absence of excess concentrations of inhibitors 
or combinations of inhibitors of amino acid transporters were also measured. Tryptophan transport at high concentration (0.5 mM) had 
low affinity and high Vmax and the LAT1 isoform of system-L was responsible for approximately 40% of the total uptake of tryptophan. 
In comparison, tryptophan transport at low concentration (50 nM) had higher affinity, lower Vmax and approximately 80% of tryptophan 
uptake was transported by system-L with LAT1 as the major isoform. The uptake of tryptophan at the low concentration was mainly 
sodium (Na+) dependent, while uptake at high substrate concentration was mainly Na+ independent. A series of different transporter 
inhibitors had varying inhibitory effects on tryptophan uptake.
This study indicates that tryptophan is transported by multiple transporters that are active at different substrate concentrations in human 
fibroblast cells. The tryptophan transport trough system-L was mainly facilitated by the LAT1 isoform, at both low and high substrate 
concentrations of tryptophan.
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Introduction
Serotonin,  an  important  neurotransmitter  in  the 
brain, is known to play an important role in   functions 
  subserving mood, anxiety, aggression, sleep,   appetite 
and  sexual  behaviour.1  Disturbed  serotonergic 
  neurotransmission is implicated in the pathogenesis 
of  schizophrenia,2  bipolar  disorder,3  depression,3 
obsessive-compulsive  disorder,4  and  generalized 
  anxiety disorder.5
Evidence  for  disturbed  serotonergic  neurotrans-
mission  in  different  neuropsychiatric  patients  was 
obtained from observations that patients with affective 
disorders and suicide attempters have lower levels of 
the serotonin metabolite (5 hydroxyindolacetic acid, 
5HIAA) in the cerebrospinal fluid (CSF) compared 
to controls.3,6–10 Since 5HIAA is believed to reflect 
  serotonin turnover in the brain,7 the findings of low 
levels of this metabolite could implicate a reduction 
in central serotonergic transmission in both mania and 
depression. Serotonin re-uptake inhibitors has shown 
to be effective in the treatment of depression and other 
psychiatric disorders.11 Tryptophan is the precursor 
for  serotonin  synthesis  and  reduced  availability  of 
tryptophan to the brain has been shown to result in 
mood changes of healthy volunteers in experimental 
studies using tryptophan depletion.12
The  rate  of  serotonin  synthesis  in  the  brain 
depends on different factors: free plasma tryptophan 
concentrations, the rate at which tryptophan crosses the 
blood-brain barrier (BBB), the affinity of   tryptophan 
to the transport protein, the enzymatic activity of tryp-
tophan hydroxylase and the kynurenine pathway that 
metabolizes more than 90% of tryptophan. Any inter-
ference with any or all of the above factors could 
influence the availability of serotonin.13–15
Disturbed  transport  of  tryptophan  across  the 
erythrocyte membranes in depressed patients16–18 and 
aberrant transport of amino acids such as tyrosine 
and  alanine  across  the  membranes  of  fibroblasts 
obtained from patients with schizophrenia and autism 
is a repeated finding in many studies.19–25 The reason 
for  aberrant  transport  of  amino  acids  across  the 
plasma  membranes  in  psychiatric  patients  has  not 
been identified; some studies have shown abnormal 
expression and dysfunctional amino acid transporters 
resulting in disturbed neurotransmission.26
Our group has functionally characterized tyrosine 
transport  in  fibroblasts  and  shown  that  tyrosine  is 
transported  into  human  fibroblasts  mainly  via  the 
sodium  (Na+)  independent  system-L  and  the  Na+ 
dependent  system-A.27  System-L  consists  of  four 
isoforms LAT1,28 LAT2,29 LAT330 and LAT431 and 
these transporters are widely expressed in the body 
and are present in both BBB and fibroblasts.32 A recent 
study by our group has shown that tyrosine is mainly 
transported through the LAT1 isoform of system-L33 
that is present in the BBB.34,35 In the same study it was 
shown that both tyrosine and alanine have affinity for 
the LAT1 and LAT2 isoforms of system-L. Tyrosine 
is  also  transported  via ATA2,  one  of  the  isoforms 
of system-A,33 that is present at the BBB36 and in 
fibroblasts.27,33
Transport of tryptophan across the plasma mem-
branes  differ  between  cell  types  in  different  cell 
lines.37 Presence of two tryptophan transport   systems 
in  human  fibroblasts  were  reported  and  that  the 
kinetic    parameters  Vmax  and  Km  differed  between 
them.38 System-1 was shown to have high affinity and 
low Vmax for tryptophan, while system-2 was shown 
to have lower affinity and higher Vmax for tryptophan. 
It was shown that the transport of tryptophan at low 
substrate  concentrations  was  Na+  dependent  while 
the transport at high substrate concentration was Na+ 
independent.38 In a recent study, a novel amino acid 
transporter with high affinity (Km value in nanomo-
lar range) and an unusual selectivity for   tryptophan 
in  human  monocyte-derived  macrophages  was 
described.39 It was indicated that tryptophan   transport 
across the brush border of placenta is through the 
LAT1 isoform of system-L, while tryptophan transport 
across the basal membrane of the placenta is through 
LAT2 isoform of system-L and system-y+L.37
The  tryptophan  transport  with  respect  to  the 
isoforms  of  system-A  and  L  and  the  tryptophan 
affinity  to  other  transporters  have  not  been  fully 
characterized in human fibroblasts. The specific aims 
of the present study were to functionally characterize 
the  tryptophan  transport  and  to  identify  the  main 
transporters of tryptophan in fibroblast cell lines from 
healthy controls.
Materials and Methods
Materials
Fibroblast cell lines obtained from healthy controls 
were used. Three randomly selected fibroblast cell lines 
(n = 3) obtained from a Biobank33 were used to study Tryptophan transport in human fibroblast cells
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Na+ dependency of tryptophan transport, to determine 
tryptophan transport at low and high   concentrations 
in the presence and absence of   different inhibitors and 
to determine tryptophan kinetic parameters at low and 
high concentration ranges. One cell line (n = 1) was 
used to study the tryptophan transport in the presence 
of tryptophan itself as a competitive inhibitor. The 
ethical committee at Karolinska Institute, Stockholm, 
Sweden approved the study.
Cell  culture  growth  media,  antibiotics,  growth 
media  supplements  and  fetal  bovine  serum  (FBS) 
were  obtained  from  Gibco  Invitrogen  cell    culture 
  (Sweden). 3H (5)-L-tryptophan with specific activity 
30  Ci/mmol  was  obtained  from  Larodan  Fine 
  Chemicals  AB  (Malmö,  Sweden).  D-Glucose  was 
obtained from Ambresco (Ohio, USA) and phosphate 
buffered  saline  (PBS)  was  from  The  National 
Veterinary  Institute  (SVA)  (Uppsala,  Sweden). All 
chemicals,  inhibitors  and  amino  acids  were  pur-
chased  from  Sigma-  Aldrich  (Stockholm,  Sweden). 
Cell  culturing  flasks  and  24  multi-well  trays  were 
purchased  from  Costar  Europe  Ltd.  Micro-well 
plates used for protein determination were purchased 
from  Nunc  (Roskilde,  Denmark).    Liquid  scintilla-
tion  cocktail  (Optiphase  Hi  Safe-3)  and  the  liquid 
scintillation  counter    (Winspectral  1414)  were  pur-
chased from PerkinElmer Life Sciences, USA. All 
amino  acid  solutions  and  inhibitor  solutions  were 
made with phosphate buffer saline solution (PBS) or 
with sodium free choline HEPES buffer and the pH 
was maintained between 7.35 and 7.4.
Methods
cell culturing
Fibroblast  cells  were  cultured  in  minimal  essential 
medium containing 10% FBS, L-glutamine (2 mM/L), 
penicillin (100 mg/ml), streptomycin (100 mg/ml) and 
Amnio-MaxTM. Cells were maintained in a humidified 
atmosphere at a temperature of 37 °C with 5% CO2 
in air. Cells were grown in tissue culture flasks for 
confluence  and  were  seeded  into  2  cm2  multiwell 
plates  to  carry  out  the  measurements.  Cells  in  the 
multiplates were grown for approximately 5 days to 
attain confluence. Cell lines between the 4th and the 
21st passage (number of splitting) were used for the 
experiments.
Uptake studies
To  functionally  characterize  the  tryptophan 
transport at low concentration, fibroblasts cultured 
in  multiwell  plates  were  washed  twice  with  PBS 
containing calcium and magnesium. The cells were 
then  pre-  incubated  for  one  hour  at  37°C  in  PBS 
with 1% D-glucose to deplete the cells of endog-
enous amino acids. The preincubation medium was 
removed and the fibroblast cells were incubated with 
uptake solution by using the cluster tray method23,40 
for  5  minutes  at  37°C. The  uptake  solution  con-
tained 50 nM of  3H (5)-L-tryptophan in combina-
tion with excess concentrations (50 µM) of different 
inhibitors (Table 1). The reaction was terminated by 
rapidly washing the cells with ice cold PBS twice. 
The cells were then lysed for 60 minutes by using 
Table 1. Inhibitors and their selectivity’s to the isoforms of both system-L and -A and other amino acid transporters and their 
effect on tryptophan uptake at low concentration (50 nM) in fibroblast cell lines from healthy controls (n = 3).
Inhibitors selectivity of inhibitors 
(reference number)
Functional transport systems  
after inhibition
Tryptophan 
uptakea
MeAIB System-A(42) System-L + otherb 95.8 (7.1)nS
Bch System-L(30) System-A + otherb 23.4 (5.1)**
neM LAT2, LAT3, LAT4(30,31) System-A and LAT1 + otherb 97.9 (12.7)nS
Tyrosine ATA2, System-L(39) y+L + otherb 18.2 (2.9)**
Phenylalanine System-L, b0+AT(39) System-A, y+L + otherb 16.5 (2.3)**
Tryptophan Tryptophan transporters(39) Otherb 10.6 (2.0)**
1MT Tryptophan transporters(39) Otherb 12.0 (1.4)**
D-Methionine LAT1(44) System-A, LAT2, LAT3, LAT4 + otherb 20.6 (3.4)**
Leucine ATA3, System-L, y+L(37) ATA1, ATA2, b0+AT + otherb 17.7 (2.8)**
Lysine ATA3, b0+AT, y+L(37) ATA1, ATA2, system-L + otherb 82.3 (27.3)nS
notes: aThe values of tryptophan uptake are presented as percentages (mean (SD)) of tryptophan uptake, compared to the percentage of tryptophan 
uptake in the absence of inhibitors set to 100%; bOther: Undefined transport system or systems. **P , 0.005.
Abbreviations: NS, not significant; LAT1, LAT2, LAT3 and LAT4, isoforms of system-L; ATA2, isoform of system-A; MeAIB, methyl-aminoisobutyric acid; 
Bch, 2-aminobicyclo heptane-2-carboxylic acid; neM, n-ethyl maleimide; 1MT, 1-methyl-L-tryptophan.Ravi et al
22  International Journal of Tryptophan Research 2011:4
0.5 M sodium hydroxide (NaOH). An aliquot from 
the cell lysate was mixed with scintillation cocktail 
and the radioactivity was assayed by liquid scintil-
lation counting. All assays were performed in trip-
licates. The uptake of tryptophan was correlated to 
total amount of protein in each well, determined by 
Bradford multi-well method41 using bovine serum 
albumin as standard.
To functionally characterize the tryptophan trans-
port at high concentration, fibroblasts were incubated 
with  0.5  mM  of  unlabelled  L-tryptophan,  3H  (5)- 
L-tryptophan in the presence or absence of excess 
concentrations  (2.5  mM)  of  different  inhibitors  or 
combinations of inhibitors (Table 2) using the same 
procedure as mentioned above.
Competitive  inhibitors  (transporter  selective 
substrates)  such  as  methyl-aminoisobutyric  acid 
(MeAIB),42  2-aminobicyclo  heptane-2-carboxylic 
acid (BCH),43 D-methionine,44 tryptophan, tyrosine, 
1-methyl-L-tryptophan  (1MT),39  leucine,37  lysine,37 
N-ethylmaleimide (NEM)31,43 or combinations of the 
above in excess concentration (50 µM or 2.5 mM) 
were used to inhibit system A and/or L and/or their 
selective isoforms or other transporters in order to 
study the tryptophan transport ability of uninhibited 
amino acid transporters. An overview of single and 
combinations of inhibitors and their selectivities for 
different transport systems are described in Tables 1 
and 2.
Sodium dependency
To test the sodium dependency of tryptophan trans-
port at high (0.5 mM) and low (50 nM) concentra-
tions, confluent fibroblasts were incubated for 5 min 
with 0.5 mM of unlabelled L-tryptophan and 3H (5)-L-
tryptophan or with 50 nM of 3H (5)-L-tryptophan. The 
uptake solutions were prepared either with PBS or 
with sodium free choline HEPES   buffer.   Termination 
of  uptake  assay  and  analysis  was    performed  as 
mentioned above.
Tryptophan Kinetics
Tryptophan kinetic parameters (Vmax and Km) at low 
and high concentrations were determined by incu-
bating  the  fibroblasts  in  the  multi  well  plate  for 
1 minute at 37 °C together with high concentration 
range (0.75 mM-2 mM) and low concentration range 
(5 µM–500 µM) of 3H (5)-L-tryptophan.   Termination 
of  uptake  assay  and  analysis  was  performed  as 
mentioned above.
calculations
Uptake  of  tryptophan  in  nmol/min/mg  protein  or 
pmol/min/mg protein was obtained from the average 
Table 2. Inhibitors, combinations of inhibitors, their selectivities’ for the isoforms of system-L and -A amino acid transporters 
and their effect on tryptophan uptake at high concentration (0.5 mM) in fibroblast cell lines from healthy controls (n = 3).
Inhibitors selectivity of inhibitors  
(reference number)
Functional transport systems 
after inhibition
Tryptophan 
uptakea
MeAIB System-A(42) System-L + otherb 98.0 (3.2)nS
Bch System-L(30) System-A + otherb 63.4 (6.9)*
neM LAT2, LAT3, LAT4(30,31) System-A and LAT1 + otherb 78.9 (16.6)nS
D-methionine LAT1(44) System-A, LAT2, LAT3, LAT4 + 60.8 (7.6)*
otherb
Tryptophan Tryptophan transporters(39) Otherb 47.61
1MT Tryptophan transporters(39) Otherb 48.6 (7.3)*
MeAIB + Bch ATA2 + system-L Otherb 54.6 (7.9)*
MLT + MeAIB Tryptophan transporters + system-A Otherb 47.4 (4.7)**
MLT + Bch Tryptophan transporters + system-L Otherb 47.4 (5.6)**
MLT +  
D-Methionine Tryptophan transporters + LAT1 Otherb 45.9 (6.3)**
MLT + neM Tryptophan transporters + LAT2, LAT3, LAT4 Otherb 29.2 (5.1)**
notes: aThe values of tryptophan uptake in the presence of inhibitors are presented as percentage (mean (SD)) of tryptophan uptake, compared to the 
percentage of tryptophan uptake in the absence of inhibitors set to 100%; bOther: Undefined transport system or systems. 1One cell line (n = 1) was used 
to carry out the experiment. *P , 0.02, **P , 0.005. 
Abbreviations: NS, not significant; LAT1, LAT2, LAT3 and LAT4, isoforms of system-L; ATA2, isoform of system-A; MeAIB, methyl-aminoisobutyric acid; 
Bch, 2-aminobicyclo heptane-2-carboxylic acid; neM, n-ethyl maleimide; 1MT, 1-methyl-L-tryptophan. Tryptophan transport in human fibroblast cells
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of  counts  per  minute  correlated  to  the  amount  of 
protein. The uptake values of tryptophan are presented 
as percentages (%) of tryptophan uptake, relative to 
tryptophan  uptake  in  the  absence  of  inhibitors  set 
to 100%. For uptake assays, each experiment was 
performed in triplicates.
Kinetic  parameters  (Vmax  and  Km)  of  tryptophan 
uptake  were  determined  according  to  Michaelis-
Menten’s equation and the double reciprocal method 
of Lineweaver and Burk. In short, the initial rates 
of  uptake  are  plotted  against  the  low  and  high 
concentration ranges to obtain the diffusion constant 
(Kd) as the slope of regression. The inverse values of 
uptake, corrected for Kd, are then fitted to a straight 
line against the inverted values of the concentrations. 
The straight line intercepting at the Y-axis gives the 
1/Vmax value and the X-axis intercept gives the -1/Km 
value. Vmax is the maximal transport capacity of the 
carrier-mediated process (nmol/min/mg protein) and 
Km is the affinity constant (the concentration at half-
saturation; µmol/l). Each experiment was performed 
in duplicates.
Statistical analysis
Kinetic  parameters  are  presented  as  means  with 
standard deviations (SD). The values of tryptophan 
uptake and inhibition in the presence and absence of 
inhibitors and sodium are presented as percentage (%) 
of tryptophan uptake. The percentage uptake values 
of tryptophan in the presence or absence of inhibitors, 
sodium  and  kinetic  parameters  of  tryptophan  at 
low  and  high  concentration  ranges  were  normally 
distributed  when  tested  with  the  Shapiro-Wilk 
test. Paired samples t-test was used to compare the 
percentage uptake values of tryptophan at different 
conditions  of  inhibition  to  uptake  of  tryptophan 
without  inhibition,  to  compare  uptake  values  of 
tryptophan in the presence and absence of sodium and 
to compare the kinetic parameters of tryptophan at low 
and high concentration ranges. A P-value below 0.05 
was considered to denote statistical significance.
Results
effect of sodium on uptake of tryptophan
The  uptake  of  tryptophan  at  high  concentration 
(0.5 mM) was lowered by 26.2% (P = 0.026) in the 
absence of Na+ ions in the uptake medium. Tryptophan 
uptake at low concentrations (50 nM) was lowered by 
71.0% (P = 0.035) in the absence of Na+ ions in the 
uptake medium (Fig. 1).
Tryptophan kinetics at low and high 
concentration ranges
The  kinetic  parameters  for  tryptophan  transport  in 
the low concentration range (5 µM–500 µM) resulted 
in a Vmax of 6.5 (1.9) nmol/min/mg protein and a Km 
of  17.1  (8.5)  µmol/L.  The  kinetic  parameters  for 
tryptophan transport in the high concentration range 
(0.75 mM–2 mM) was for Vmax 8.8 (2.2) nmol/min/mg 
protein and for Km 459.3 (138.7) µmol/L. Thus, the 
transport  of  tryptophan  at  low  concentrations  had 
a lower Vmax (P = 0.030) and around 25 fold higher 
affinity (P = 0.029) (Fig. 2) in comparison to tryptophan 
transport at high concentration range (Fig. 2 insert).
effect of different inhibitors on uptake  
of low concentration of tryptophan (50 nM)
Uptake of tryptophan at the low concentration (50 nM) 
was studied in the presence of excess concentration 
(50 µM) of different inhibitors. Uptake of tryptophan 
in the presence of MeAIB was inhibited by only 4.2% 
(Table 1).
Uptake of tryptophan in the presence of BCH was 
23.4% and NEM inhibited around 2% of tryptophan 
uptake, which demonstrates a less specific role of the 
isoforms LAT2, LAT3, and LAT4 in the uptake of 
tryptophan at low concentrations (Table 1).
Tyrosine,  a  substrate  for  System-A  (ATA2)  and 
system-L  (LAT1,  LAT2)  inhibited  around  82%  of 
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Figure 1. Uptake of tryptophan into fibroblast cell lines from three (n = 3) 
healthy  controls  in  the  presence  and  absence  of  sodium  (na+)  ions. 
Absence of na+ ions in the uptake medium resulted in a 26.2% decrease 
in uptake of tryptophan (0.5 mM) (P = 0.026) (A) and a 71.0% decrease 
in the uptake of tryptophan (50 nM) (P = 0.035) (B), when compared to 
uptake of tryptophan in the presence of na+ ions in the uptake medium.Ravi et al
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tryptophan  uptake.  Phenylalanine  a  substrate  for 
LAT1, LAT2 and system-b0+AT inhibited around 83.5% 
of tryptophan uptake (Table 1).
Around 90% of tryptophan uptake was inhibited 
by both tryptophan and 1MT, a tryptophan analogue. 
D-methionine inhibited tryptophan uptake by 80%, 
which indicates that the LAT1 isoform of system-L 
is  the  major  (approximately  80%)  transporter  of 
tryptophan at low concentrations. Leucine, a   substrate 
for ATA3, system-L and system-y+L inhibited around 
82.3% of tryptophan uptake (Table 1). When lysine, 
a substrate for ATA3, System-b0+AT and system- y+L, 
was used as an inhibitor it resulted in around 17.7% 
inhibition of tryptophan uptake. These results indicate 
that  system-L  and  other  undefined  transporters 
together transport the major part of tryptophan at low 
concentrations.
effect of different inhibitors  
on uptake of high concentration  
of tryptophan (0.5 mM)
Uptake  of  tryptophan  at  the  high  concentration 
(0.5  mM)  was  studied  in  the  presence  of  excess 
concentrations  (2.5  mM)  of  different  inhibitors  or 
combinations of inhibitors (Table 2).
MeAIB, a system-A inhibitor, did not result in any 
significant  inhibition  of  tryptophan  uptake.  In  the 
presence  of  BCH,  a  system-L  inhibitor,  36.6%  of 
tryptophan uptake was inhibited, indicating that 63.4% 
of tryptophan at high concentration is transported by 
transport systems other than system-L. When LAT1, 
one of the isoforms of system-L, was inhibited by 
D-methionine  it  resulted  in  39.2%  inhibition  of 
tryptophan uptake. When LAT2, LAT3 and LAT4, 
isoforms of systems-L, where inhibited by NEM, it 
resulted  in  around  21.1%  inhibition  of  tryptophan 
uptake (Table 2).
When using 1MT as an inhibitor it resulted in an 
inhibition of tryptophan uptake by 51.4%. To check 
if 1MT has the same inhibitory effect as tryptophan, 
tryptophan was used as an inhibitor at a concentration of 
2.5 mM to inhibit 3H (5)-L-tryptophan uptake (0.5 mM) 
and it resulted in an inhibition of 52.4% of tryptophan 
uptake (Table 2).
effect of combinations of inhibitors  
on uptake of high concentration  
of tryptophan (0.5 mM)
MeAIB and BCH together inhibited the tryptophan 
uptake by 45.4%, indicating that 54.6% of tryptophan 
is transported through a system other than system-A 
and system-L (Table 2).
When using 1MT and MeAIB in combination it 
resulted  in  52.6%  inhibition  of  tryptophan  uptake 
and when 1MT and BCH were used in combination 
52.6% of tryptophan uptake was inhibited. This also 
indicates  that  approximately  50%  of  tryptophan  is 
transported through a system other than system-A and 
system-L (Table 2).
1MT and D-methionine together inhibited around 
54.1% of tryptophan uptake, indicating that LAT2, 
LAT3, LAT4 and a system other than system-A and 
system-L (LAT1) is responsible for around 45.9% of 
tryptophan uptake (Table 2).
1MT and NEM together inhibited around 70.8% 
of tryptophan uptake, indicating that the system other 
than system-A and system-L and LAT1 accounts for 
29.2% of tryptophan uptake. These results also show 
that NEM slightly inhibits other tryptophan specific 
systems than system-A and system-L (Table 2).
Discussion
Functional  characterization  of  tryptophan  transport 
at both low and high concentrations was carried out 
in  the  present  study.  It  was  demonstrated  that  the 
  transport of tryptophan differed at low vs. high sub-
strate concentrations and that low and high   tryptophan 
concentrations  differed  regarding  Na+  dependency, 
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Figure 2. Division of kinetic analysis of the tryptophan uptake at high 
(0.75–2 mM) and low (5–500 µM) concentration ranges. Initial rates of 
uptake corrected for the diffusion constant Y (nmol/min/mg protein) is 
plotted  against  low  and  high  (insert)  substrate  concentration  S  (mM) 
according to the double reciprocal method of Lineweaver and Burk. each 
point represents the means of six determinations of three cell lines.Tryptophan transport in human fibroblast cells
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kinetic parameters, and effects on tryptophan uptake 
of different transporter inhibitors.
Uptake  of  tryptophan  at  high  concentration 
(0.5  mM)  is  mostly  Na+  independent,  while 
tryptophan uptake at low concentration (50 nM) is 
mainly Na+ dependent. Absence of Na+ ions in the 
uptake  solution  resulted  in  around  26%  inhibition 
of  tryptophan  uptake  at  the  high  concentration 
(0.5 mM) and a 71% inhibition of tryptophan uptake 
at the low concentration (50 nM). These results are 
in accordance with the study by Groth et al, 1972,38 
which  demonstrated  that  tryptophan  uptake  in  the 
absence of Na+ is inhibited at low concentrations but 
not at high concentrations.
The  kinetic  parameters  of  tryptophan  differed 
between low and high concentrations.
Tryptophan  transport  at  the  low  concentration 
range (5 µM–500 µM) has a low Vmax and higher 
affinity  indicated  by  a  low  Km  value,  while  tryp-
tophan  transport  at  the  high  concentration  range 
(0.75 mM–2 mM) has a higher Vmax and lower affinity 
indicated by a higher Km value. This observation is 
also in accordance with Groth et al, 1972,38 and this 
indicates the involvement of more than one trans-
porter in the uptake of tryptophan.
Uptake of tryptophan at low concentration (50 nM) 
was mainly through the system-L, since the system-L 
inhibitor BCH inhibited around 76.6% of tryptophan 
uptake. Confirmation of this finding was demonstrated 
by  obtaining  approximately  the  same  percentage 
of  inhibition  of  tryptophan  uptake  in  the  presence 
of  tyrosine,  phenylalanine  and  leucine,  which  also 
are  inhibitors  for  system-L.  The  LAT1  isoform  of 
system-L  is  the  major  transporter  of  tryptophan  at 
low  concentration,  as  demonstrated  when  using 
D-methionine  as  an  inhibitor,  which  resulted  in 
around 80% inhibition of tryptophan uptake. In the 
presence of MeAIB, the inhibitor for system-A, and 
NEM,  the  inhibitor  for  LAT2,  LAT3  and  LAT4, 
almost no inhibition of the uptake of tryptophan at low 
concentration was shown, which indicates minor role 
of these transporters in the uptake of tryptophan at low 
concentrations. Tyrosine, which is mainly transported 
by the LAT1 isoform and to a smaller extent by the 
ATA2 isoform,33 when used as an inhibitor it resulted in 
around 81% inhibition of tryptophan uptake showing 
that tryptophan transport at low concentrations may 
be in similar fashion as tyrosine transport.
The uptake of tryptophan at low concentration is 
with high affinity, is mainly Na+ dependent and has 
different  inhibitory  effects  of  the  inhibitors,  when 
compared to tryptophan uptake at high concentration. 
This may indicate the presence of a hitherto uniden-
tified transporter functioning at low concentrations 
of  tryptophan. Alternatively,  it  could  be  a  variant 
of a known transporter that has different functional 
properties due to an alteration in the structure of the 
transporter  protein. As  an  example,  the  functional 
properties  of  system-L  are  known  to  alter  due  to 
different light-chain subunits.39,45
Tryptophan uptake at high concentration (0.5 mM) 
through  system-L  was  around  36.6%.  This  is 
demonstrated by using BCH as system-L selective 
inhibitor.  System-A  has  no  specific  role  in  the 
uptake  of  tryptophan  at  high  concentration,  which 
is  demonstrated  by  using  MeAIB  as  a  system-A 
inhibitor.  The  role  of  the  isoforms  (LAT1,  LAT2, 
LAT3, and LAT4) of system-L in uptake of tryptophan 
was also studied in the present study by using the 
inhibitors of the isoforms. D-methionine used as an 
inhibitor for LAT1 isoform showed that the uptake of 
tryptophan (at high concentration) through LAT1 was 
around 40%. The role of LAT2, LAT3, and LAT4 in 
the uptake of tryptophan (at high concentration) was 
around 21%, which was demonstrated by using NEM 
as an inhibitor for LAT2, LAT3, and LAT4 isoforms. 
The percentage of tryptophan uptake by individual 
isoforms of system-L are obtained when each isoform 
is  inhibited  by  a  inhibitor,  but  when  system-L  is 
working in the absence of inhibitors the isoforms of 
system-L could be working in parallel with different 
transport capacities.
When using either 1MT, which is a close structural 
analogue of tryptophan, or tryptophan as inhibitors at 
a concentration of 2.5 mM, it resulted in only about 
48.6% uptake of tryptophan (at high concentration). 
This  shows  that  the  rest  of  tryptophan  uptake  is 
probably through a transport system that transports 
higher  concentrations  of  tryptophan  ie,  more  than 
2.5 mM. This transport system seems to be different 
from system-A and system-L as it was not inhibited 
completely by either MeAIB or BCH. This transport 
system is probably a Na+ independent system since 
uptake  of  tryptophan  at  high  concentration  was 
found to be mainly Na+ independent. The reason for 
tryptophan and 1MT not being able to completely Ravi et al
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inhibit  the  uptake  of  tryptophan  could  be  that  the 
transport system that transports tryptophan at high 
concentrations is not totally saturated at a competitive 
inhibitor concentration of 2.5 mM.
The results of the present study indicate that the 
uptake of tryptophan into human fibroblasts is sub-
served  by  different  transport  systems  at  different 
substrate  concentrations.  Tryptophan  uptake  at 
different concentrations is different in terms of Na+ 
dependency, kinetic parameters, substrate selectivity, 
and  inhibitory  effects  of  different  competitive 
inhibitors or transporter selective inhibitors. Moreover, 
the present findings show that tryptophan transport 
through system-L is mainly facilitated through the 
LAT1 isoform, at both low and high concentrations 
of tryptophan. However, these observations are only 
based on functional activity of the transporters and 
not based on data at the protein level. Hence, further 
biochemical studies with more selective or specific 
transporter inhibitors are necessary to understand the 
transport of tryptophan across cell membranes, but 
such inhibitors are presently not available.
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